{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:33:07Z","timestamp":1788845587792,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Elizabeth Rosenthal Bone Bequest"},{"name":"Sticks & Stones Foundation"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.bone.2017.04.016","type":"journal-article","created":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T05:32:26Z","timestamp":1493443946000},"page":"96-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta"],"prefix":"10.1016","volume":"101","author":[{"given":"David G.","family":"Little","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Mikulec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kneissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tegan L.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Schindeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Munns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9418","key":"10.1016\/j.bone.2017.04.016_bb0005","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bone.2017.04.016_bb0010","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1210\/jc.2013-1505","article-title":"New genes in bone development: what's new in osteogenesis imperfecta","volume":"98","author":"Marini","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bone.2017.04.016_bb0015","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ocl.2013.06.010","article-title":"Advances in the orthopedic management of osteogenesis imperfecta","volume":"44","author":"Laron","year":"2013","journal-title":"Orthop. Clin. North Am."},{"issue":"1","key":"10.1016\/j.bone.2017.04.016_bb0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40200-014-0109-y","article-title":"Bisphosphonate therapy in pediatric patients","volume":"13","author":"Eghbali-Fatourechi","year":"2014","journal-title":"J. Diabetes Metab. Disord."},{"issue":"2","key":"10.1016\/j.bone.2017.04.016_bb0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2017.04.016_bb0030","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: Meta-analysis of placebo-controlled trials","volume":"18","author":"Hald","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2017.04.016_bb0035","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.bone.2017.04.016_bb0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.maturitas.2014.04.016","article-title":"Anti-sclerostin antibodies: utility in treatment of osteoporosis","volume":"78","author":"Clarke","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2017.04.016_bb0045","article-title":"Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy","volume":"18","author":"Moe","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2017.04.016_bb0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jbmr.2059","article-title":"Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity","volume":"29","author":"Chang","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2017.04.016_bb0055","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2106\/JBJS.L.00285","article-title":"Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model","volume":"95","author":"Virk","year":"2013","journal-title":"J. Bone Joint Surg. Am."},{"issue":"2","key":"10.1016\/j.bone.2017.04.016_bb0060","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1359\/jbmr.090720","article-title":"Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model","volume":"25","author":"Daley","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2017.04.016_bb0065","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1073\/pnas.90.5.1701","article-title":"Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta","volume":"90","author":"Chipman","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.bone.2017.04.016_bb0070","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2017.04.016_bb0075","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/jbmr.2996","article-title":"Suppression of sclerostin alleviates radiation-induced bone loss by protecting bone-forming cells and their progenitors through distinct mechanisms","volume":"32","author":"Chandra","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2017.04.016_bb0080","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/jbmr.2278","article-title":"Mechanical load increases in bone formation via a sclerostin-independent pathway","volume":"29","author":"Morse","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.04.016_bb0085","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bone.2014.08.016","article-title":"Disruption of glucocorticoid signaling in chondrocytes delays metaphyseal fracture healing but does not affect normal cartilage and bone development","volume":"69","author":"Tu","year":"2014","journal-title":"Bone"},{"issue":"16","key":"10.1016\/j.bone.2017.04.016_bb0090","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.jbiomech.2008.09.028","article-title":"Bisphosphonate treatment in the oim mouse model alters bone modeling during growth","volume":"41","author":"Rao","year":"2008","journal-title":"J. Biomech."},{"issue":"4","key":"10.1016\/j.bone.2017.04.016_bb0095","doi-asserted-by":"crossref","first-page":"345","DOI":"10.59566\/IJBS.2009.5345","article-title":"Pamidronate alters the growth plate in the oim mouse model for osteogenesis imperfecta","volume":"5","author":"Evans","year":"2009","journal-title":"Int. J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.bone.2017.04.016_bb0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bone.2004.10.006","article-title":"Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse","volume":"36","author":"Misof","year":"2005","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2017.04.016_bb0105","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00198-011-1742-7","article-title":"Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta","volume":"23","author":"Bargman","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2017.04.016_bb0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jor.20469","article-title":"The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta","volume":"26","author":"Delos","year":"2008","journal-title":"J. Orthop. Res."},{"issue":"2","key":"10.1016\/j.bone.2017.04.016_bb0115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bone.2013.01.023","article-title":"Therapeutic impact of low amplitude high frequency whole body vibrations on the osteogenesis imperfecta mouse bone","volume":"53","author":"Vanleene","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.04.016_bb0120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.04.016_bb0125","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.bone.2017.04.016_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway","volume":"6","author":"Wijenayaka","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2017.04.016_bb0135","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/jbmr.2824","article-title":"Osteoblast malfunction caused by cell stress response to procollagen misfolding in \u03b12(I)-G610C mouse model of osteogenesis imperfecta","volume":"8","author":"Mirigian","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.04.016_bb0140","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bone.2016.04.011","article-title":"Bone mineral properties in growing Col1a2(+\/G610C) mice, an animal model of osteogenesis imperfecta","volume":"87","author":"Masci","year":"2016","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328217301588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328217301588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T21:19:19Z","timestamp":1719177559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328217301588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":28,"alternative-id":["S8756328217301588"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2017.04.016","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2017.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2017 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}